PharmaBlock Sciences (Nanjing), Inc.

Shenzhen Stock Exchange 300725.SZ

PharmaBlock Sciences (Nanjing), Inc. Price to Sales Ratio (P/S) on January 27, 2025: 3.54

PharmaBlock Sciences (Nanjing), Inc. Price to Sales Ratio (P/S) is 3.54 on January 27, 2025, a 2.13% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

PharmaBlock Sciences (Nanjing), Inc. 52-week high Price to Sales Ratio (P/S) is 5.28 on October 08, 2024, which is 49.06% above the current Price to Sales Ratio (P/S).
PharmaBlock Sciences (Nanjing), Inc. 52-week low Price to Sales Ratio (P/S) is 2.80 on February 05, 2024, which is -21.03% below the current Price to Sales Ratio (P/S).
PharmaBlock Sciences (Nanjing), Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 3.65.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 300725.SZ

PharmaBlock Sciences (Nanjing), Inc.

CEO	Dr. Minmin Yang Ph.D.
IPO Date	Nov. 10, 2017
Location	China
Headquarters	10 Xuefu Road
Employees	2,455
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Petrochemicals

Description

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years